The iconic rise of Viagra has consistently remained a example of pharmaceutical success, however its future within the broader industry now raises questions about long-term yields . Alternative versions are eroding exclusivity , prompting concerns that investing in companies closely tied to Viagra's former influence could be a problematic strategy,